Alpha-2 Vasoconstriction Compositions for Rebound Hyperemia Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing vasoconstrictor formulations cause rebound hyperemia and other side effects due to high alpha-1 receptor stimulation, leading to undesirable clinical sequelae like ischemia and medicamentosa, with no effective means to induce long-term vasoconstriction without these issues.

Innovation Solution

Using highly selective alpha-2 adrenergic receptor agonists at low concentrations (below 0.05% weight by volume) to minimize alpha-1 receptor activation, thereby reducing rebound hyperemia and achieving effective vasoconstriction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high concentration alpha agonists are used for vasoconstriction, then vasoconstriction effectiveness is improved, but rebound hyperemia and ischemia occur

Engineering Contradiction:

Improvevasoconstriction effectivenessVSAvoidrebound hyperemia and ischemia

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the concentration parameter of the alpha agonist from high (0.1-0.2% for brimonidine) to low (below 0.05%), which fundamentally alters the receptor activation profile. This parameter change shifts the balance from excessive alpha-1 stimulation (causing rebound hyperemia) to selective alpha-2 stimulation (providing sustained vasoconstriction without rebound effects), thereby resolving the contradiction between effectiveness and harmful side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the adrenergic receptor activation by using highly selective alpha-2 agonists that preferentially activate alpha-2 receptors over alpha-1 receptors. This segmentation allows independent control of vasoconstriction (via alpha-2) without triggering the harmful rebound hyperemia pathway (via alpha-1), thus resolving the technical contradiction

Inventive Principle:

Principle #1Segmentation

2Reliability

If alpha-1 receptor agonists are used for vasoconstriction, then vasoconstriction is achieved, but rebound hyperemia and medicamentosa occur

Engineering Contradiction:

Improvevasoconstriction effectVSAvoidrebound hyperemia and medicamentosa

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts the harmful alpha-1 receptor activation component from the vasoconstriction mechanism by using highly selective alpha-2 agonists. This extraction eliminates the source of rebound hyperemia and medicamentosa while preserving the desired vasoconstriction effect through selective alpha-2 receptor stimulation

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces highly selective alpha-2 agonists as intermediary substances that mediate vasoconstriction through alpha-2 receptors without activating alpha-1 receptors. These intermediaries provide the vasoconstriction effect while avoiding the harmful rebound hyperemia pathway, thus resolving the contradiction

Inventive Principle:

Principle #24Intermediary (Mediator)

3Duration of action of stationary object

If known alpha adrenergic receptor agonists are used for long-term treatment, then vasoconstriction is maintained, but rebound hyperemia and medicamentosa develop

Engineering Contradiction:

Improveduration of vasoconstrictionVSAvoidrebound hyperemia and medicamentosa

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by using highly selective alpha-2 agonists from the outset to establish a vasoconstriction mechanism that does not lead to rebound hyperemia. This preliminary selection of selective agonists prevents the development of harmful side effects even with long-term use, resolving the contradiction between duration and harmful factors

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent employs low concentrations of highly selective alpha-2 agonists that can be used frequently without accumulating harmful effects. Unlike traditional alpha agonists that cause rebound hyperemia with repeated use, these selective agonists maintain safety and efficacy over long periods, resolving the contradiction between duration of use and harmful side effects

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method provides safe and long-term vasoconstriction with significantly reduced hyperemia and ischemia, effectively treating conditions like nasal congestion and ocular issues while minimizing side effects.

Implementation Method 1

Vascular constriction is known to be mediated by α-adrenergic receptors. α-2 adrenergic receptors are presently classified into three subtypes based on their pharmacological and molecular characterization: α-2A/D, α-2B, and α-2C. The α-2A, α-2B, and α-2C subtypes appear to regulate arterial and/or venular contraction in some vascular beds

Methodology Applied

Scientific EffectAdrenergic receptor agonism:

Data Source

PatentUS20250248929A1Vasoconstriction compositions and methods of use

Publication Date: 2025.08.07 EYE THERAPIES LLC

AI summary

The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.